Airsculpt Technologies, Inc. has reported its third-quarter results, revealing a decline in revenue and case volume. The company also announced the completion of a refinancing deal that extends its debt maturity to 2031. This update is significant as it highlights the ongoing challenges faced by the company and the broader medical services industry.

Airsculpt Technologies, Inc. operates in the SIC category of Services-Offices & Clinics of Doctors of Medicine (SIC 8011). The company trades on the Nasdaq under the ticker symbol AIRS. It is recognized as an emerging growth company and has been filing reports with the SEC regularly, with the most recent filing dated November 6, 2026.

According to the filing, the company stated, "While our third quarter results were below expectations, we identified the key drivers and are addressing them with a sense of urgency." The company reported revenue of $31.9 million for the third quarter, an 8.7% decline from $35.0 million in the same period last year. Additionally, case volume decreased by 9.6% on a same-store sales basis, totaling 2,483 cases.

Furthermore, Airsculpt reported a net loss of $7.2 million, which is an improvement from a net loss of $9.5 million in the third quarter of the previous year. Adjusted EBITDA was $0.4 million, down from $3.0 million in the prior year. The company also performed approximately 250 GLP-1-related procedures during the quarter, which accounted for about 10% of total cases.

The filing indicates that the company is taking steps to address its challenges. Airsculpt has reduced its full-year 2026 revenue guidance to a range of $144 million to $146 million, down from a previous estimate of $151 million to $157 million. Adjusted EBITDA guidance has also been lowered to a range of $9 million to $10 million, compared to the earlier range of $12 million to $14 million.

This update may have implications for various stakeholders, including investors, employees, and competitors in the medical services sector. The refinancing of the term loan, which extends to 2031, may provide Airsculpt with the necessary liquidity to navigate these challenges. The company raised $7.2 million from an at-the-market offering program, which helped pay down $7.0 million of its debt.

Looking ahead, the filing does not specify what the next steps will be for Airsculpt Technologies. However, the company is expected to continue focusing on its operational priorities and addressing the factors that have impacted its recent performance.